PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33741008-5	2021	Furthermore, a derivative of the microtubule-targeting drug maytansine (DM1) was incorporated in the PGNSs.	Maytansine	60-70	DM1 protein kinase	Homo sapiens	72-75	
31318460-1	2019	BACKGROUND: In the phase 3 MARIANNE trial, trastuzumab emtansine (T-DM1) with or without pertuzumab showed noninferior progression-free survival and better tolerability than trastuzumab plus a taxane (HT) for the first-line treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced breast cancer.	Maytansine	55-64	DM1 protein kinase	Homo sapiens	68-71	
33536280-9	2021	A de novo anti-CLDN6 monoclonal antibody conjugated with cytotoxic agent (Mertansine) DM1 (CLDN6-DM1) was developed.	Maytansine	74-84	DM1 protein kinase	Homo sapiens	86-89	
33536280-9	2021	A de novo anti-CLDN6 monoclonal antibody conjugated with cytotoxic agent (Mertansine) DM1 (CLDN6-DM1) was developed.	Maytansine	74-84	DM1 protein kinase	Homo sapiens	97-100	
32570117-4	2020	One such therapy is the antibody drug conjugate (ADC) trastuzumab emtansine (T-DM1), a combination of trastuzumab and the cytotoxic antimicrotubule agent DM1.	Maytansine	66-75	DM1 protein kinase	Homo sapiens	79-82	
33371333-1	2020	In this study, HER2 RNA aptamers were conjugated to mertansine (DM1) and the anti-cancer effectiveness of the conjugate was evaluated in HER2-overexpressing breast cancer models.	Maytansine	52-62	DM1 protein kinase	Homo sapiens	64-67	
29456473-4	2017	T-DM1 combines the anti-tumor activity of trastuzumab with that of DM1, a highly potent derivative of the anti-microtubule agent maytansine, resulting in increased anti-tumor activity.	Maytansine	129-139	DM1 protein kinase	Homo sapiens	2-5	
29456473-4	2017	T-DM1 combines the anti-tumor activity of trastuzumab with that of DM1, a highly potent derivative of the anti-microtubule agent maytansine, resulting in increased anti-tumor activity.	Maytansine	129-139	DM1 protein kinase	Homo sapiens	67-70	
34913340-2	2022	Herein, we constructed a robust cetuximab-polymersome-mertansine nanodrug (C-P-DM1) for highly potent and targeted therapy of epidermal growth factor receptor (EGFR)-positive solid tumors.	Maytansine	54-64	DM1 protein kinase	Homo sapiens	79-82	
24308017-1	2013	Trastuzumab emtansine is an antibody-drug conjugate comprised of the receptor tyrosine-protein kinase erbB-2 (HER2) antibody trastuzumab, and a derivative of the cytostatic agent maytansinoid DM1, covalently linked by a thiol linker.	Maytansine	12-21	DM1 protein kinase	Homo sapiens	192-195	
22475266-1	2012	Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprised of trastuzumab and the cytotoxic agent DM1 (derivative of maytansine) linked by a stable linker N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).	Maytansine	128-138	DM1 protein kinase	Homo sapiens	25-28	
22475266-1	2012	Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate comprised of trastuzumab and the cytotoxic agent DM1 (derivative of maytansine) linked by a stable linker N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC).	Maytansine	128-138	DM1 protein kinase	Homo sapiens	109-112	
34440055-1	2021	A maytansin derivative, DM1, is a promising therapeutic compound for treating tumors, but is also a highly poisonous substance with various side effects.	Maytansine	2-11	DM1 protein kinase	Homo sapiens	24-27	
34365852-1	2022	INTRODUCTION: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate and its survival advantage has been shown in advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer.	Maytansine	30-39	DM1 protein kinase	Homo sapiens	43-46